ArticleVaccine2026
Dengue vaccines: The role of a correlate of protection in evaluating vaccine safety and risk.
Article in Vaccine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Dengue remains a significant global health challenge, with incidence rising and over half the world's population at risk. Vaccines could play an important role in controlling dengue, but without a validated correlate of protection (CoP), vaccine development relies on large, costly, and complex phase 3 field efficacy trials that are often underpowered for evaluating efficacy and safety by individual DENV serotypes in individuals who have never been infected with a dengue virus (i.e., DENV-naïve individuals). A validated CoP would help developers make informed decisions about the best vaccine candidates for testing in costly phase 3 field trials. A CoP might enable licensure of dengue vaccines based on efficacy endpoint trials of shorter duration and use of immunogenicity data to bridge efficacy data to other populations, which could accelerate the pathway from vaccine trials to operational dengue vaccination programs. Recognizing the urgent need for vaccine development and licensure, a group of experts in dengue vaccinology convened in San Juan, Puerto Rico, from March 14-15, 2024, to define a research agenda for establishing a CoP. The meeting brought together experts from academia, government, U.S. regulatory agencies, and public health organizations who identified key barriers to CoP validation, discussed lack of assay standardization and limited regulatory consensus, and identified the most promising CoP candidates. Experts agreed that neutralizing antibodies to unique epitopes on each serotype (i.e., type-specific antibodies) are the most promising biomarker for DENV-naïve individuals (the most challenging subgroup for establishing safety and efficacy) and emphasized the need for harmonized assays and validation studies using clinical trial samples. The group also discussed the role of alternative trial modalities, such as human challenge studies and nonhuman primate models, in supplementing regulatory submissions where phase 3 efficacy data may be incomplete. This article outlines the key research priorities identified at the meeting and provides a framework for advancing CoP validation to accelerate dengue vaccine development, licensure, and implementation. By aligning scientific, regulatory, and industry efforts around these priorities, the field can move more quickly toward broad access to safe and effective dengue vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.